TrumpRx Scrutinized: Does It Help or Hurt Americans?

0:00On April 22nd, Senate Finance Committee members put Health Secretary Robert F. Kennedy Jr. under the microscope this week over Trump R.X. questioning. If the drug discount platform truly helps everyday folks or just boost big farmer profits, Senators highlighted how prices on Trump R.X. run higher than overseas and even some spots right here in the U.S. with the slight offering just 80 of. The 24,000 FDA approved drugs, mostly the common ones. They also called out eligibility rules that block millions on Medicare or Medicaid from buying in, leaving many Americans high and dry without real, savings. Senator Peter Welch from Vermont hammered home the point that drug companies saw $1.3 trillion dollar market surge, pocketing $177 billion in profits, up from $107 billion, while prices actually climb for nearly all 16 participating firms. Kennedy pushback saying, benefits only kick in if production moves stateside, but Welch

1:00wrapped it calling Trump R.X. straight up fraudulent, floating. A bill to cap U.S. prices at global averages that the Secretary seemed open to tweaking. I'm Cory with the story. That's your entertainment and celebrity news today update. AI powered and always trending.